BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 19337204)

  • 1. Impact of androgen deprivation therapy on racial/ethnic disparities in the survival of older men treated for locoregional prostate cancer.
    Holmes L; Chan W; Jiang Z; Ward D; Essien EJ; Du XL
    Cancer Control; 2009 Apr; 16(2):176-85. PubMed ID: 19337204
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Racial, Socioeconomic, and Geographic Disparities in the Receipt, Timing to Initiation, and Duration of Adjuvant Androgen Deprivation Therapy in Men with Prostate Cancer.
    Nguyen C; Lairson DR; Swartz MD; Du XL
    J Racial Ethn Health Disparities; 2019 Feb; 6(1):133-142. PubMed ID: 29959759
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Race and Time to Receipt of Androgen Deprivation Therapy Among Men With Metastatic Prostate Cancer.
    Cobran EK; Young HN; Chen RC; Chen X; Reeves J; Godley PA; Shah S
    J Natl Med Assoc; 2019 Jun; 111(3):246-255. PubMed ID: 30389146
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative effectiveness of radical prostatectomy with adjuvant radiotherapy versus radiotherapy plus androgen deprivation therapy for men with advanced prostate cancer.
    Jang TL; Patel N; Faiena I; Radadia KD; Moore DF; Elsamra SE; Singer EA; Stein MN; Eastham JA; Scardino PT; Lin Y; Kim IY; Lu-Yao GL
    Cancer; 2018 Oct; 124(20):4010-4022. PubMed ID: 30252932
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Racial treatment trends in localized/regional prostate carcinoma: 1992-1999.
    Underwood W; Jackson J; Wei JT; Dunn R; Baker E; Demonner S; Wood DP
    Cancer; 2005 Feb; 103(3):538-45. PubMed ID: 15612083
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of ethnicity on the outcome of men with metastatic, hormone-sensitive prostate cancer.
    Bernard B; Muralidhar V; Chen YH; Sridhar SS; Mitchell EP; Pettaway CA; Carducci MA; Nguyen PL; Sweeney CJ
    Cancer; 2017 May; 123(9):1536-1544. PubMed ID: 28055108
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effectiveness of androgen deprivation therapy in prolonging survival of older men treated for locoregional prostate cancer.
    Holmes L; Chan W; Jiang Z; Du XL
    Prostate Cancer Prostatic Dis; 2007; 10(4):388-95. PubMed ID: 17486111
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Race/ethnicity and the receipt of watchful waiting for the initial management of prostate cancer.
    Shavers VL; Brown ML; Potosky AL; Klabunde CN; Davis WW; Moul JW; Fahey A
    J Gen Intern Med; 2004 Feb; 19(2):146-55. PubMed ID: 15009794
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Improved Survival With Prostate Radiation in Addition to Androgen Deprivation Therapy for Men With Newly Diagnosed Metastatic Prostate Cancer.
    Rusthoven CG; Jones BL; Flaig TW; Crawford ED; Koshy M; Sher DJ; Mahmood U; Chen RC; Chapin BF; Kavanagh BD; Pugh TJ
    J Clin Oncol; 2016 Aug; 34(24):2835-42. PubMed ID: 27325855
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Survival Outcomes of Men with Lymph Node-positive Prostate Cancer After Radical Prostatectomy: A Comparative Analysis of Different Postoperative Management Strategies.
    Touijer KA; Karnes RJ; Passoni N; Sjoberg DD; Assel M; Fossati N; Gandaglia G; Eastham JA; Scardino PT; Vickers A; Cozzarini C; Montorsi F; Briganti A
    Eur Urol; 2018 Jun; 73(6):890-896. PubMed ID: 29042125
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risks of Major Long-Term Side Effects Associated with Androgen-Deprivation Therapy in Men with Prostate Cancer.
    Nguyen C; Lairson DR; Swartz MD; Du XL
    Pharmacotherapy; 2018 Oct; 38(10):999-1009. PubMed ID: 30080934
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cardiovascular and Skeletal-related Events Following Localized Prostate Cancer Treatment: Role of Surgery, Radiotherapy, and Androgen Deprivation.
    Wallis CJ; Mahar AL; Satkunasivam R; Herschorn S; Kodama RT; Lee Y; Kulkarni GS; Narod SA; Nam RK
    Urology; 2016 Nov; 97():145-152. PubMed ID: 27502032
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Race/ethnicity and the intensity of medical monitoring under 'watchful waiting' for prostate cancer.
    Shavers VL; Brown M; Klabunde CN; Potosky AL; Davis W; Moul J; Fahey A
    Med Care; 2004 Mar; 42(3):239-50. PubMed ID: 15076823
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Racial/ethnic differences in receipt of pelvic lymph node dissection among men with localized/regional prostate cancer.
    Hayn MH; Orom H; Shavers VL; Sanda MG; Glasgow M; Mohler JL; Underwood W
    Cancer; 2011 Oct; 117(20):4651-8. PubMed ID: 21456009
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Patterns of Declining Use and the Adverse Effect of Primary Androgen Deprivation on All-cause Mortality in Elderly Men with Prostate Cancer.
    Sammon JD; Abdollah F; Reznor G; Pucheril D; Choueiri TK; Hu JC; Kim SP; Schmid M; Sood A; Sun M; Kibel AS; Nguyen PL; Menon M; Trinh QD
    Eur Urol; 2015 Jul; 68(1):32-9. PubMed ID: 25457017
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differential use of medical versus surgical androgen deprivation therapy for patients with metastatic prostate cancer.
    Borno HT; Lichtensztajn DY; Gomez SL; Palmer NR; Ryan CJ
    Cancer; 2019 Feb; 125(3):453-462. PubMed ID: 30444526
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Trends and racial differences in the use of androgen deprivation therapy for metastatic prostate cancer.
    Carson AP; Howard DL; Carpenter WR; Taylor YJ; Peacock S; Schenck AP; Godley PA
    J Pain Symptom Manage; 2010 May; 39(5):872-81. PubMed ID: 20471547
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Race and mortality risk after radiation therapy in men treated with or without androgen-suppression therapy for favorable-risk prostate cancer.
    Kovtun KA; Chen MH; Braccioforte MH; Moran BJ; D'Amico AV
    Cancer; 2016 Dec; 122(23):3608-3614. PubMed ID: 27490845
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fifteen-year survival outcomes following primary androgen-deprivation therapy for localized prostate cancer.
    Lu-Yao GL; Albertsen PC; Moore DF; Shih W; Lin Y; DiPaola RS; Yao SL
    JAMA Intern Med; 2014 Sep; 174(9):1460-7. PubMed ID: 25023796
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Associations between Peripheral Thromboembolic Vascular Disease and Androgen Deprivation Therapy in Asian Prostate Cancer Patients.
    Lu YC; Huang CY; Yeh HM; Hong JH; Chang CH; Muo CH; Chung SD; Yang TK; Jaw FS; Chung CJ
    Sci Rep; 2019 Oct; 9(1):14231. PubMed ID: 31578427
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.